Semaglutide vs Tirzepatide
Semaglutide and tirzepatide are both once-weekly injectable incretin therapies used for type 2 diabetes and weight management; semaglutide acts on the GLP-1 pathway, while tirzepatide acts on both the GIP and GLP-1 pathways.
Vial summary · compiled from public records
At a glance
Semaglutide
Sold as Ozempic, Wegovy, Rybelsus
- Category
- Weight Loss
- FDA / legal status
- Compounding Restricted
- Route
- Subcutaneous, oral
Tirzepatide
Sold as Mounjaro, Zepbound
- Category
- Weight Loss
- FDA / legal status
- Compounding Restricted
- Route
- Subcutaneous
Side by side
| Field | Semaglutide | Tirzepatide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| Brand names | Ozempic, Wegovy, Rybelsus | Mounjaro, Zepbound |
| FDA / legal status | Compounding Restricted | Compounding Restricted |
| Evidence tier | FDA Approved | FDA Approved |
| Administration route | Subcutaneous, oral | Subcutaneous |
| Compounding access | Compounding limited to documented case-by-case 503A need | Compounding limited to documented case-by-case 503A need |
| Providers on Vial | 27 listed | 22 listed |
| Typical price band | $ to $$ | $ to $$ |
Verified providers offering each
Ranked by Confidence Rating, Vial’s 0 to 100 score built from federal and state public records. The score evaluates the provider, not the compound.
About each compound
About Semaglutide
A synthetic glucagon-like peptide-1 (GLP-1) receptor agonist, semaglutide mimics the incretin hormone GLP-1 to stimulate glucose-dependent insulin secretion, suppress glucagon release, and slow gastric emptying. The compound also acts on hypothalamic receptors to reduce appetite and food intake. Primary clinical applications include the management of type 2 diabetes mellitus and chronic weight management in individuals with obesity or overweight with weight-related comorbidities.
About Tirzepatide
A synthetic dual agonist peptide, tirzepatide activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors to enhance insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite. The compound produces significant improvements in glycemic control and body weight reduction. Primary clinical applications include treatment of type 2 diabetes mellitus and chronic weight management in adults with obesity.
Descriptions compiled from public FDA records and manufacturer labeling where available. Not medical advice.
This page evaluates compliance signals, not clinical outcomes. Consult a licensed physician before starting any therapy, medication, or treatment. Vial does not provide medical advice.